Regencell Bioscience Holdings Limited
RGCHealthcare|Drug Manufacturers - Specialty & Generic|HK
$5.27
+0.00 (+0.00%)
DCF Value
$0.03
Tangible Book / Share
$0.03
Cash / Share
$0.03
Financials
Financial Snapshot
Market Cap
$2.61B
Enterprise Value
$2.60B
Revenue (TTM)
$0.00
Net Income (TTM)
-$15.3M
Cash & Investments
$14.2M
Net Cash
$13.9M
Free Cash Flow (TTM)
-$7.7M
Operating CF (TTM)
-$7.7M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$14.2M
Quarterly Burn
$1.9M
Monthly Burn
$641.3K
Est. Runway
~7.4 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $243.3K | $387.0K | $59.4K | $16.4M | $11.6M | $8.0M | $4.9M | $14.2M | $14.2M | |
| Operating Cash Flow | -$391.0K | -$726.6K | -$767.3K | -$5.3M | -$5.0M | -$4.0M | -$3.1M | -$7.7M | -$7.7M | |
| Free Cash Flow | -$391.0K | -$844.4K | -$767.3K | -$6.0M | -$5.0M | -$4.0M | -$3.3M | -$7.7M | -$7.7M | |
| Capital Expenditure | $0.00 | -$117.8K | $1.00 | -$780.9K | -$27.4K | -$5.4K | -$152.7K | $0.00 | -$2.00 | |
| Financing Cash Flow | $481.0K | $988.1K | $439.7K | $22.4M | $134.9K | $102.3K | $0.00 | $16.9M | $16.9M |
R&D Spending
R&D (TTM)
$2.2M
R&D Intensity
—
R&D Growth vs Prior
+73.0%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $228.2K | $386.2K | $438.3K | $2.5M | $1.6M | $1.1M | $948.3K | $1.3M | $2.2M | |
| SG&A | $162.8K | $426.1K | $943.0K | $5.1M | $4.7M | $2.9M | $2.4M | $10.0M | $12.8M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $9.5K | $26.5K | $604.4K | $769.7K | $745.6K | $392.7K | $404.5K | $404.5K | |
| Gross Profit | $0.00 | -$9.5K | -$26.5K | -$604.4K | -$769.7K | -$745.6K | -$392.7K | -$404.5K | -$404.5K | |
| R&D | $228.2K | $386.2K | $438.3K | $2.5M | $1.6M | $1.1M | $948.3K | $1.3M | $2.2M | |
| SG&A | $162.8K | $426.1K | $943.0K | $5.1M | $4.7M | $2.9M | $2.4M | $10.0M | $12.8M | |
| Operating Income | -$391.0K | -$812.4K | -$1.4M | -$7.6M | -$6.3M | -$4.7M | -$3.8M | -$11.7M | -$15.5M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$391.0K | -$812.4K | -$1.3M | -$7.6M | -$6.1M | -$4.4M | -$3.6M | -$11.7M | -$15.3M | |
| Net Income | -$391.0K | -$812.4K | -$1.3M | -$7.4M | -$5.9M | -$4.3M | -$3.6M | -$11.7M | -$15.3M | |
| EPS (Diluted) | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | |
| EBITDA | $0.00 | -$802.9K | -$1.4M | -$7.0M | -$5.3M | -$3.6M | -$3.2M | -$11.3M | -$14.9M | |
| Shares Out. (M) | 480.40 | 480.40 | 480.40 | 494.49 | 494.49 | 494.49 | 494.49 | 494.60 | 494.70 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $243.3K | $387.0K | $59.4K | $6.4M | $1.6M | $3.0M | $2.4M | $14.2M | $14.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $10.0M | $10.0M | $5.0M | $2.5M | $0.00 | $0.00 | |
| Total Current Assets | $243.3K | $387.0K | $66.8K | $16.4M | $11.6M | $8.1M | $4.9M | $14.2M | $14.2M | |
| Total Assets | $243.3K | $514.0K | $340.1K | $18.0M | $12.6M | $8.4M | $5.8M | $14.7M | $14.7M | |
| Total Current Liabilities | $2.1M | $3.2M | $4.3M | $577.8K | $606.9K | $193.6K | $663.7K | $1.3M | $1.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $2.1M | $3.2M | $4.3M | $938.0K | $632.3K | $219.5K | $895.3K | $1.4M | $1.4M | |
| Stockholders' Equity | -$1.8M | -$2.7M | -$4.0M | $17.1M | $12.0M | $8.2M | $4.9M | $13.3M | $13.3M | |
| Retained Earnings | -$1.8M | -$2.7M | -$4.0M | -$11.4M | -$17.3M | -$21.6M | -$25.2M | -$36.9M | -$36.9M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$391.0K | -$726.6K | -$767.3K | -$5.3M | -$5.0M | -$4.0M | -$3.1M | -$7.7M | -$7.7M | |
| Capital Expenditure | $0.00 | -$117.8K | $1.00 | -$780.9K | -$27.4K | -$5.4K | -$152.7K | $0.00 | -$2.00 | |
| Free Cash Flow | -$391.0K | -$844.4K | -$767.3K | -$6.0M | -$5.0M | -$4.0M | -$3.3M | -$7.7M | -$7.7M | |
| Investing Cash Flow | $0.00 | -$117.8K | $0.00 | -$10.8M | $59.0K | $5.2M | $2.7M | $2.5M | $2.5M | |
| Financing Cash Flow | $481.0K | $988.1K | $439.7K | $22.4M | $134.9K | $102.3K | $0.00 | $16.9M | $16.9M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $18.7M | $18.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.8M | -$1.8M | |
| Net Debt Issuance | $481.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $2.8M | $930.0K | $449.3K | $244.8K | $0.00 | $1.6M | |
| Net Change in Cash | $90.0K | $143.7K | -$327.6K | $6.4M | -$4.9M | $1.4M | -$542.1K | $11.8M | $11.2M |
Dilution Tracker
Shares Outstanding
496M
5-Year Share Growth
+3.0%
Stock Issuance (TTM)
$18.7M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 480.40 | 480.40 | 480.40 | 494.49 | 494.49 | 494.49 | 494.49 | 494.60 | 494.70 | |
| Change vs Prior % | — | 0.0% | 0.0% | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $18.7M | $18.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.8M | -$1.8M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $2.8M | $930.0K | $449.3K | $244.8K | $0.00 | $1.6M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 21.3% | 30.6% | 33.7% | -43.5% | -48.8% | -52.3% | -73.7% | -87.7% | -160.6% | |
| ROA % | -160.7% | -158.0% | -395.9% | -41.2% | -46.5% | -51.0% | -62.3% | -79.4% | -79.4% | |
| ROIC % | -160.5% | -193.9% | 437.6% | -42.7% | -50.4% | -57.0% | -69.8% | -85.9% | -85.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | -178.0% | -2184.5% | -27.3% | 3.1% | 47.3% | -3.0% | |
| Operating Income | 0.0% | -107.8% | -70.0% | -451.5% | 17.6% | 24.5% | 20.4% | -211.0% | |
| Net Income | 0.0% | -107.8% | -65.8% | -451.2% | 20.9% | 26.7% | 16.7% | -226.5% | |
| EPS (Diluted) | 0.0% | -109.2% | -64.7% | -435.7% | 20.7% | 26.9% | 17.2% | -229.2% | |
| Operating Cash Flow | 0.0% | -85.8% | -5.6% | -586.4% | 5.8% | 19.4% | 22.2% | -147.2% | |
| Free Cash Flow | 0.0% | -116.0% | 9.1% | -688.2% | 17.5% | 19.7% | 18.5% | -135.6% | |
| R&D Expense | 0.0% | 69.2% | 13.5% | 473.1% | -37.0% | -32.6% | -11.1% | 37.0% | |
| SG&A Expense | 0.0% | 161.8% | 121.3% | 441.4% | -8.1% | -37.7% | -17.0% | 312.5% | |
| Total Assets | 0.0% | 111.3% | -33.8% | 5197.6% | -30.0% | -33.1% | -31.8% | 155.9% | |
| Book Value / Share | 0.0% | -44.2% | -50.8% | 515.1% | -29.8% | -31.5% | -40.9% | 174.6% | |
| Debt | 0.0% | 47.5% | 19.9% | -79.1% | -39.9% | -81.5% | 535.0% | -45.7% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B195.29
10Y Low / Med / High5.08 / 26.39 / 1733.67
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.03
Tangible Book / Share
$0.03
Net Current Assets / Share
$0.03
Graham Net-Net
$0.03
Cash / Share
$0.03
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -340.02 | -162.54 | -98.69 | -60.71 | -50.95 | -9.71 | -2366.67 | -256.96 | -223.31 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -72.20 | -50.08 | -33.21 | 26.39 | 24.92 | 5.08 | 1733.67 | 225.64 | 195.29 | |
| EV/EBITDA | 0.00 | -168.68 | -100.65 | -63.61 | -56.44 | -10.75 | -2639.60 | -264.86 | -229.63 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
1130.98
Safe
Piotroski F-Score
2
Weak
Dividends
Frequency
Quarterly
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Feb 15, 2018 | Feb 26, 2018 | $8.36 | Quarterly |
| Dec 1, 2017 | Dec 15, 2017 | $8.36 | Quarterly |
| Aug 31, 2017 | Sep 15, 2017 | $8.36 | Quarterly |
| Jun 1, 2017 | Jun 15, 2017 | $8.36 | Quarterly |
| Mar 1, 2017 | Mar 15, 2017 | $8.36 | Quarterly |
| Dec 1, 2016 | Dec 15, 2016 | $8.36 | Quarterly |
| Aug 31, 2016 | Sep 15, 2016 | $8.36 | Quarterly |
| Jun 2, 2016 | Jun 16, 2016 | $8.36 | Quarterly |
| Mar 2, 2016 | Mar 15, 2016 | $8.36 | Quarterly |
| Dec 2, 2015 | Dec 15, 2015 | $8.36 | Quarterly |
| Sep 2, 2015 | Sep 15, 2015 | $8.36 | Quarterly |
| May 29, 2015 | Jun 12, 2015 | $8.36 | Quarterly |
| Feb 27, 2015 | Mar 13, 2015 | $8.36 | Quarterly |
| Dec 2, 2014 | Dec 15, 2014 | $8.36 | Quarterly |
| Sep 3, 2014 | Sep 15, 2014 | $8.36 | Quarterly |
| May 30, 2014 | Jun 13, 2014 | $8.36 | Quarterly |
| Feb 28, 2014 | Mar 14, 2014 | $8.36 | Quarterly |
| Dec 2, 2013 | Dec 13, 2013 | $7.98 | Quarterly |
| Sep 5, 2013 | Sep 17, 2013 | $7.98 | Quarterly |
| May 31, 2013 | Jun 14, 2013 | $7.98 | Quarterly |